Why Concert Pharmaceuticals Inc. Shares Were Hammered

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Concert Pharmaceuticals , a clinical-stage biotechnology company developing a wide array of small molecule drugs to treat everything from nervous system disorders to cancer, sank nearly 11% during Thursday's trading session after announcing a public offering before the opening bell.

So what: According to Concert Pharmaceuticals' press release, it agreed to sell 3.3 million shares of its common stock at $15.15 per share, an 8.5% discount from yesterday's closing price. The expected net proceeds from the stock sale will be approximately $46.7 million, with a 30-day option available for the underwriters to purchase up to an additional 495,000 shares of common stock. Presumably, the offering will be used to fund ongoing research and development.

Source: Concert Pharmaceuticals.

Now what: What you're witnessing here is one of the biggest dangers of buying clinical-stage biotechnology stocks: dilution. Because clinical-stage biotech companies have few ways of generating cash (i.e., licensing deals or collaborations), they often turn to common stock offerings in order to raise money. Unfortunately for existing shareholders this winds up diluting the shares they already own. For instance, the 3.3 million share offering will increase Concert's outstanding share count by a whopping 18% -- and it could even be higher if the underwriters exercise their buy option. In other words, shareholders should probably be thankful that Concert only shed 11% when the outstanding share count is moving higher by 18%!

The good news is that after taxes, Concert should have in excess of $120 million in cash and cash equivalents, basing this number on the $79 million it had in cash and cash equivalents as of its most recently reported quarter. With operating cash flow of negative $30 million over the trailing 12-month period, this would imply that Concert probably has a three or four year cash runway to develop its pipeline.

My personal opinion is that Concert is nothing more than a radar stock at the moment. Even though it's likely solved its interim cash concerns, and it does have a handful of drug development partners, its most advanced partnered product, AVP-786, is being targeted a major depressive disorder and Alzheimer's disease -- two indications where the failure rate for clinical drugs is pretty high. I'd rather hang out on the sidelines and wait for positive data and/or a decision from the Food and Drug Administration than be caught on the wrong side of bad clinical data.

This coming blockbuster will make every biotech jealous

The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .

The article Why Concert Pharmaceuticals Inc. Shares Were Hammered originally appeared on

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More